CliffBio
small molecule

EXSERVAN

RILUZOLE

Loss of exclusivity—loss of exclusivity
CompanyAquestive Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameEXSERVAN
Active ingredientRILUZOLE
Strength50MG
Dosage formFILM
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2019
Marketing statusDISCN

More from Aquestive Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EXSERVAN patent cliff — loss of exclusivity — | CliffBio